Ofloxacin Tablets

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

The main ingredient of this product is: ofloxacin.

This product is a white film-coated tablet, which appears off-white or slightly yellow after removing the film coating.

It is mainly used for acute and chronic bacterial infections of urinary, reproductive, digestive, respiratory systems, skin, soft tissues, etc. caused by sensitive bacteria. It includes patients in internal medicine, surgery, urology, obstetrics and gynecology, ophthalmology, otolaryngology, dermatology, etc.

Oral administration: Adults: 0.2-0.3g at a time, twice a day or as directed by a doctor.

Nausea, vomiting, stomach and abdominal discomfort, insomnia, dizziness, headache, rash and increased serum alanine aminotransferase may occur occasionally, but they are generally tolerated and disappear after drug discontinuation.

It should not be used by people who are allergic to quinolones, children, pregnant and lactating women, and patients with epilepsy.

Precautions for children: The safety of this product in infants and adolescents under 18 years of age has not been determined. However, this product can cause joint lesions when used in several young animals. Therefore, it should not be used in children and adolescents under 18 years of age. Precautions for pregnancy and lactation: Animal experiments have not confirmed that quinolones are teratogenic, but studies on the use of drugs in pregnant women have not yet reached a clear conclusion. Since this drug can cause joint lesions in underage animals, it is contraindicated for pregnant women, and lactating women should suspend breastfeeding when using this product. Precautions for the elderly: Elderly patients often have impaired renal function, and since this product is partially excreted through the kidneys, it needs to be used in reduced doses.

1 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2 When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the liver clearance of theophylline, a prolonged blood elimination half-life (t1/2b), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Therefore, theophylline blood drug concentration should be measured and the dose adjusted when used in combination. 3 Cyclosporine combined with this product can increase its blood drug concentration. Cyclosporine blood concentration must be monitored and the dose adjusted. 4 This product can enhance the anticoagulant effect of the latter when used with the anticoagulant warfarin. When used in combination, the patient's prothrombin time should be closely monitored. 5 Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. 6 This product has an antagonistic effect with nitrofurantoin and is not recommended for combined use. 7. Antacids containing aluminum and magnesium can reduce the oral absorption of this product and should not be used together.

Keep away from light and store in sealed container.

0.2g

Tentative two years

China Resources Double-Crane Pharmaceutical Co., Ltd.

• Founded in:

  1997-05-16

• Address:

  No. 1, Lize East 2nd Road, Wangjing, Chaoyang District, Beijing

• Tax NO.:

  91110000633796475U

• Registered Funds:

  1,038,836,522 yuan

• Website:

  Log in to view

• Email:

  Log in to view